Atomi Financial Group Inc. Buys 6,385 Shares of Johnson & Johnson (NYSE:JNJ)

Atomi Financial Group Inc. lifted its stake in Johnson & Johnson (NYSE:JNJ) by 20.8% during the first quarter, Holdings Channel reports. The fund owned 37,153 shares of the company’s stock after acquiring an additional 6,385 shares during the quarter. Atomi Financial Group Inc.’s holdings in Johnson & Johnson were worth $5,877,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Christopher J. Hasenberg Inc bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $31,000. Keener Financial Planning LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $40,000. WFA Asset Management Corp boosted its stake in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at $44,000. Finally, Disciplined Equity Management Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at $45,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on JNJ shares. Morgan Stanley decreased their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Monday, June 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, July 1st. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Down 0.2 %

Shares of JNJ stock traded down $0.29 on Monday, hitting $149.59. 2,676,525 shares of the stock were exchanged, compared to its average volume of 7,240,449. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $360.02 billion, a P/E ratio of 9.30, a price-to-earnings-growth ratio of 2.52 and a beta of 0.52. The business has a 50-day moving average of $147.94 and a 200 day moving average of $153.46. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.68 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.